OAR 836-200-0555
Assessments Against Prescription Drug Manufacturers

(1)

Once annually, no later than October 1, all reporting manufacturers will pay an assessment of $400. The director may by order reduce the fees assessed for any specific year.

(2)

Once annually, no later than October 1, reporting manufacturers that have filed one or more reports under OAR 836-200-0515 (Threshold for Reporting Drug Price Increase) to 836-200-0530 (Form and Manner Requirements for Drug Pricing Reporting) between August 1 of the previous year and July 31 of the current year must pay an additional assessment for each report filed.

(3)

For the purposes of subsection (2), the director shall determine the amount of the assessment by subtracting the revenue collected under subsection (1) from the amount of revenue needed to cover the department’s estimated expenses in administering Oregon Laws 2018, chapter 7, section 2 and OAR 836-200-0500 (Purpose and Statutory Authority) to 836-200-0550 (Consumer Notices to the Department), and dividing the resulting amount by the total number of filings subject to assessment between August 1 of the previous year and July 31 of the current year. The director shall determine the amount of revenue needed by considering the legislatively approved expenditures for administration of Oregon Laws 2018, chapter 7, section 2 and OAR 836-200-0500 (Purpose and Statutory Authority) to 836-200-0555 (Assessments Against Prescription Drug Manufacturers), as well as the timing of cash revenues and expenditures.
(4) The revenue collected under subsections (1) and (2) of this section must be used solely for expenses incurred in the administration of Oregon Laws 2018, chapter 7, section 2 and OAR 836-200-0500 (Purpose and Statutory Authority) to 836-200-0555 (Assessments Against Prescription Drug Manufacturers).

(5)

A manufacturer must pay each assessment imposed under this rule no later than 30 days after the date of the assessment by the department. A manufacturer must pay interest at nine percent per annum on any assessment that is not paid when due.

Source: Rule 836-200-0555 — Assessments Against Prescription Drug Manufacturers, https://secure.­sos.­state.­or.­us/oard/view.­action?ruleNumber=836-200-0555.

836–200–0000
Statutory Authority 836–200–0010
Assessments 836–200–0020
Filing Procedures 836–200–0030
Form 10 K and Other Financial Stability Filings 836–200–0040
Reimbursement Insurance Policy 836–200–0050
Registration Requirements Not Exclusive 836–200–0055
Annual Report 836–200–0060
Service on Registrant 836–200–0100
Notice, Collision Damage Waivers 836–200–0105
Statutory Authority 836–200–0110
Registration Procedures 836–200–0120
Warranty 836–200–0130
Reimbursement Insurance Policy 836–200–0140
Registration Requirements Not Exclusive 836–200–0200
License, Discount Medical Plan Organization 836–200–0210
Renewal of expired license 836–200–0215
One-time processing fee, cancelled application 836–200–0220
License Requirement Not Exclusive 836–200–0250
Purpose and Authority 836–200–0255
Registration of Contracting Entity 836–200–0300
Statement of Purpose 836–200–0305
Retainer Medical Practice Application for Certification 836–200–0310
Retainer Medical Practice Application for Renewal 836–200–0315
Disclosures 836–200–0401
Statement of Purpose 836–200–0406
Application Requirements for Pharmacy Benefit Manager 836–200–0411
Renewal of Pharmacy Benefit Registration 836–200–0416
Registration Requirements Not Exclusive 836–200–0421
Service on Registrant 836–200–0436
Submission of Complaints 836–200–0440
Market Conduct Requirements for Pharmacy Benefit Managers 836–200–0500
Purpose and Statutory Authority 836–200–0505
Definitions 836–200–0510
Account Generation Requirement 836–200–0515
Threshold for Reporting Drug Price Increase 836–200–0520
Threshold for Reporting New Specialty Drug 836–200–0525
Expectations of Reporting Manufacturers 836–200–0530
Form and Manner Requirements for Drug Pricing Reporting 836–200–0535
Additional Information Requests 836–200–0540
Information Claimed to be Trade Secret 836–200–0545
Public Disclosure of Prescription Drug Manufacturer Filings 836–200–0550
Consumer Notices to the Department 836–200–0555
Assessments Against Prescription Drug Manufacturers 836–200–0560
Civil Penalties
Last Updated

Jun. 8, 2021

Rule 836-200-0555’s source at or​.us